Melanoma progression despite infiltration by in Vivo-primed TRP-2-specific T cells

Journal of Immunotherapy

Volumn 32, Issue 2, 2009, Pages 129-139

  Singh, Vinod ^a   Ji, Qingyong ^b   Feigenbaum, Lionel ^c   Leighty, Robert M ^d   Hurwitz, Arthur A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adoptive immunotherapy; Melanoma; T cells; T cell receptor transgene

Indexed keywords

DENDRITIC CELL VACCINE; TYROSINASE RELATED PROTEIN 2; AUTOANTIGEN; DOPACHROME ISOMERASE; ISOMERASE; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PEPTIDE SVYDFFVWL; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DEPIGMENTATION; EFFECTOR CELL; EMBRYO; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG NODULE; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; T LYMPHOCYTE RECEPTOR GENE; TRANSGENE; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; CELL LINE, TUMOR; CROSS-PRIMING; FEMALE; IMMUNOTHERAPY, ADOPTIVE; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 63649127254     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819144d7     Document Type: Article

References (40)

1. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994; 180:347-352.
2. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179: 1005-1009.
3. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993;178: 489-495.
4. Wang RF, Robbins PF, Kawakami Y, et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995;181:799-804.
5. Wang RF, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996;184:2207-2216.
6. Engelhard VH, Bullock TN, Colella TA, et al. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev. 2002; 188:136-146.
7. Kawai K, Ohashi PS. Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature. 1995;374:68-69.
8. Theobald M, Biggs J, Hernandez J, et al. Tolerance to p53 by A2. 1-restricted cytotoxic T lymphocytes. J Exp Med. 1997; 185:833-841.
9. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity. 2000; 13:829-840.
10. Zehn D, Bevan MJ. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity. 2006;25: 261-270.
11. Morgan DJ, Kreuwel HT, Fleck S, et al. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol. 1998;160:643-651.
12. Sandberg JK, Franksson L, Sundback J, et al. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol. 2000; 165:25-33.
13. Fields LE, Loh DY. Organ injury associated with extrathymic induction of immune tolerance in doubly transgenic mice. Proc Natl Acad Sci USA. 1992;89:5730-5734.
14. Hernandez J, Aung S, Redmond WL, et al. Phenotypic and functional analysis of CD8( + ) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J Exp Med. 2001;194:707-717.
15. Ohlen C, Kalos M, Hong DJ, et al. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen. J Immunol. 2001;166: 2863-2870.
16. Ohlen C, Kalos M, Cheng LE, et al. CD8( + ) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med. 2002;195: 1407-1418.
17. Bendle GM, Holler A, Pang LK, et al. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res. 2004;64:8052-8056.
18. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185:453-459.
19. Parkhurst MR, Fitzgerald EB, Southwood S, et al. Identification of a shared HLA-A0201 -restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998;58:4895-4901.
20. Bronte V, Apolloni E, Ronca R, et al. Genetic vaccination with "self tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000;60:253-258.
21. Schreurs MW, Eggert AA, de Boer AJ, et al. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 2000;60:6995-7001.
22. Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J Immunol. 2005;175:1456-1463.
23. van Elsas A, Sutmuller RP, Hurwitz AA, et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001;194:481-489.
24. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19:81-84.
25. Steitz J, Bruck J, Lenz J, et al. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. J Invest Dermatol. 2005;124:144-150.
26. Currier JR, Robinson MA. Spectratype/immunoscope analysis of the expressed TCR repertoire. Curr Protoc Immunol. 2001;Chapter 10:Unit 10.28.
27. Wonderlich J, Shearer G, Livingstone A, et al. Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol. 2006; Chapter 3:Unit 3.11.
28. Zhumabekov T, Corbella P, Tolaini M, et al. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods. 1995; 185: 133-140.
29. Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immuno-logical ignorance. Proc Natl Acad Sci USA. 1999;96: 2233-2238.
30. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003; 281:65-78.
31. Gallegos AM, Bevan MJ. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med. 2004;200:1039-1049.
32. Bonasio R, Scimone ML, Schaerli P, et al. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol. 2006;7:1092-1100.
33. Kurts C, Sutherland RM, Davey G, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA. 1999;96:12703-12707.
34. + T cells is transient and depends on avidity. J Immunol. 1995;155:2339-2349.
35. Spiotto MT, Yu P, Rowley DA, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via cross-presentation by bone marrow-derived stromal cells. Immunity. 2002;17:737-747.
36. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001 ;411:1058-1064.
37. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004;173:7209-7216.
38. + T cells. J Exp Med. 2003; 198:569-580.
39. + T cells. Cancer Res. 2004;64:1 140-1145.
40. + T cells in patients with melanoma. J Immunol. 2005;175:6169-6176.